NEW YORK (GenomeWeb News) – Genomind, a firm developing genetic tests focused on psychiatry and neurology, announced today the closing of a $5 million financing round.

Claritas Capital led the round, which will be used to grow Chalfont, Penn.-based Genomind and its product portfolio. Its lead test is the Genecept Assay, a saliva-based test that assesses ten genes to help clinicians make treatment decisions for patients with depression and other psychiatric disorders. With today's funding, the company plans to increase adoption of the test, Genomind CEO Ronald Dozoretz said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.